BONE VOID FILLER CONSISTING

Brand Owner (click to sort) Address Description
BEAST Paragon 28, Inc. 14445 Grasslands Drive Englewood CO 80112 Bone void filler consisting of natural materials; Demineralized bone matrix consisting of natural materials for use in bone grafts and bone implants;
BEAST 100 Paragon 28, Inc. 14445 Grasslands Drive Englewood CO 80112 Bone void filler consisting of natural materials;BEAST ONE HUNDRED;
BEAST PLUS Paragon 28, Inc. 14445 Grasslands Drive Englewood CO 80112 Bone void filler consisting of natural materials; Demineralized bone matrix consisting of natural materials for use in bone grafts and bone implants;
INTERSEP EXACTECH, INC. 2320 NW 66th Court Gainesville FL 32653 Bone void filler consisting of synthetic materials;
MATRIFORM XTANT MEDICAL HOLDINGS, INC. 664 Cruiser Lane Belgrade MT 59714 Bone void filler consisting of synthetic materials;
MGNUM Paragon 28, Inc. 14445 Grasslands Drive Englewood CO 80112 Bone void filler consisting of natural materials;MAGNESIUM NUM;
OSTEOSCAF Skeletal Regeneration, Inc. 4808 Research Drive San Antonio TX 78240 bone void filler consisting of synthetic materials;
THE BOB Paragon 28, Inc. 14445 Grasslands Drive Englewood CO 80112 Bone void filler consisting of natural materials; Demineralized bone matrix consisting of natural materials for use in bone grafts and bone implants;
UNIFUZE ZAVATION MEDICAL PRODUCTS 220 Lakeland Pkwy Flowood MS 39232 Bone void filler consisting of synthetic materials; bone graft material, namely, bone void fillers consisting of artificial materials; bone implants composed of artificial materials for orthopedic applications;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention provides a composition including an isolated or recombinant peptide component that has osteogenic cell proliferative activity. The peptide, which promotes proliferation of osteoblasts, is useful for treatment of fractures, as a filler in deficient sites of bone, for inhibition of decrease in bone substance related to osteoporosis and periodontic diseases, and for prevention of fractures associated with osteoporosis and rheumatoid arthritis. The peptide, or cells that have been genetically engineered to produce the peptide, can be combined with a bone-compatible matrix to facilitate slow release of the peptide to a treatment site and/or provide a structure for developing bone.